All Stories

  1. Soluble-microneedle enhance three T-cell activation signals as efficient tumor vaccines for melanoma prevention and treatment

    Article • Journal of Controlled Release, July 2025, Elsevier

    Wei Zhao

  2. Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging

    Article • Analytical Chemistry, June 2025, American Chemical Society (ACS)

    Wei Zhao

  3. Discovery of environment-sensitive fluorescent ligands for SHP2 imaging in living cells and tumor sections

    Article • European Journal of Medicinal Chemistry, June 2025, Elsevier

    Wei Zhao

  4. Population pharmacokinetics and clinical assessment of linezolid in pediatric bacterial infections

    Article • Antimicrobial Agents and Chemotherapy, May 2025, ASM Journals

    Wei Zhao

  5. Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up

    Article • The Lancet Child & Adolescent Health, May 2025, Elsevier

    Wei Zhao

  6. Machine learning approach for dosage individualization of azithromycin in children with community‐acquired pneumonia

    Article • British Journal of Clinical Pharmacology, April 2025, Wiley

    Wei Zhao

  7. Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans

    Article • Cancer Chemotherapy and Pharmacology, January 2025, Springer Science + Business Media

    Wei Zhao

  8. Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial

    Article • Clinical Microbiology and Infection, January 2025, Elsevier

    Wei Zhao

  9. Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia

    Article • European Journal of Medicinal Chemistry, December 2024, Elsevier

    Wei Zhao

  10. Population Pharmacokinetics and Dose Optimization of Piperacillin in Infants and Children with Pneumonia

    Article • Pediatric Drugs, November 2024, Springer Science + Business Media

    Wei Zhao

  11. Optimal dosing regimen of caspofungin in adolescents with allogeneic haematopoietic stem cell transplantation

    Article • Journal of Antimicrobial Chemotherapy, August 2024, Oxford University Press (OUP)

    Wei Zhao

  12. TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation

    Article • Molecular Cancer Research, August 2024, American Association for Cancer Research (AACR)

    Wei Zhao

  13. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future

    Article • Advanced Drug Delivery Reviews, August 2024, Elsevier

    Wei Zhao

  14. Piperacillin/tazobactam treatment in children: evidence of subtherapeutic concentrations

    Article • Frontiers in Pharmacology, July 2024, Frontiers

    Wei Zhao

  15. Machine Learning Approach in Dosage Individualization of Isoniazid for Tuberculosis

    Article • Clinical Pharmacokinetics, July 2024, Springer Science + Business Media

    Wei Zhao

  16. Optimal use of β-lactams in neonates: machine learning-based clinical decision support system

    Article • EBioMedicine, July 2024, Elsevier

    Wei Zhao

  17. Machine Learning: A Potential Therapeutic Tool to Facilitate Neonatal Therapeutic Decision Making

    Article • Pediatric Drugs, June 2024, Springer Science + Business Media

    Wei Zhao

  18. Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation

    Article • Journal of Antimicrobial Chemotherapy, May 2024, Oxford University Press (OUP)

    Wei Zhao

  19. Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia

    Article • The Journal of Clinical Pharmacology, March 2024, Wiley

    Wei Zhao

  20. Population pharmacokinetics and dose optimization of levofloxacin in elderly patients with pneumonia

    Article • British Journal of Clinical Pharmacology, February 2024, Wiley

    Wei Zhao

  21. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1

    Article • Scientific Reports, January 2024, Springer Science + Business Media

    Wei Zhao

  22. Population pharmacokinetics of antibacterial agents in the older population: a literature review

    Article • Expert Review of Clinical Pharmacology, January 2024, Taylor & Francis

    Wei Zhao

  23. Pharmacokinetics and bioavailability of a new long-acting insulin analog in healthy Chinese volunteers: an open, randomized, single-dose, two-period and two-sequence cross-over study

    Article • Frontiers in Pharmacology, December 2023, Frontiers

    Wei Zhao

  24. Accuracy of antibiotic concentrations in drug dispensing in neonates: a laboratory-based study

    Article • BMJ Paediatrics Open, December 2023, BMJ

    Wei Zhao

  25. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects

    Article • European Journal of Pharmaceutical Sciences, December 2023, Elsevier

    Wei Zhao

  26. Recombinant Klotho alleviates vancomycin-induced acute kidney injury by upregulating anti-oxidative capacity via JAK2/STAT3/GPx3 axis

    Article • Toxicology, November 2023, Elsevier

    Wei Zhao

  27. Individualized Use of 6‐Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial

    Article • Clinical Pharmacology & Therapeutics, October 2023, Wiley

    Wei Zhao

  28. A first‐in‐human phase I study of SHR‐1906, a humanized monoclonal antibody against connective tissue growth factor, in healthy participants

    Article • Clinical and Translational Science, October 2023, Wiley

    Wei Zhao

  29. Machine Learning: A New Approach for Dose Individualization

    Article • Clinical Pharmacology & Therapeutics, September 2023, Wiley

    Wei Zhao

  30. Meropenem Clearance in a Child With End-stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy: A Case Report and Literature Review

    Article • The Pediatric Infectious Disease Journal, September 2023, Wolters Kluwer Health

    Wei Zhao

  31. Editorial: Model-based evaluation of antimicrobial agents in children—volume II

    Article • Frontiers in Pharmacology, August 2023, Frontiers

    Wei Zhao

  32. Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates

    Article • Clinical Pharmacokinetics, June 2023, Springer Science + Business Media

    Professor karel allegaert , Wei Zhao

  33. Regulatory considerations for paediatric drug evaluation in China

    Article • BMJ Paediatrics Open, May 2023, BMJ

    Wei Zhao

  34. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring

    Article • Expert Review of Clinical Pharmacology, February 2023, Taylor & Francis

    Wei Zhao

  35. Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients

    Article • British Journal of Clinical Pharmacology, February 2023, Wiley

    Wei Zhao

  36. A liquid chromatography-tandem mass spectrometry method for simultaneous quantification of thirty-nine tyrosine kinase inhibitors in human plasma

    Article • Journal of Pharmaceutical and Biomedical Analysis, February 2023, Elsevier

    Wei Zhao

  37. Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis

    Article • Children, December 2022, MDPI AG

    Wei Zhao

  38. Epithelial lining fluid concentrations of ceftriaxone in children with community‐acquired pneumonia

    Article • British Journal of Clinical Pharmacology, December 2022, Wiley

    Wei Zhao

  39. Systematic review of efficacy, safety and pharmacokinetics of intravenous and intraventricular vancomycin for central nervous system infections

    Article • Frontiers in Pharmacology, November 2022, Frontiers

    Wei Zhao

  40. General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children

    Article • British Journal of Clinical Pharmacology, November 2022, Wiley

    Wei Zhao

  41. ‘Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants’–authors’ response

    Article • Journal of Antimicrobial Chemotherapy, October 2022, Oxford University Press (OUP)

    Wei Zhao

  42. Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children

    Article • Frontiers in Pharmacology, October 2022, Frontiers

    Wei Zhao

  43. BMJ Paediatrics Openand the Global South: an open call towards editorial diversity and inclusion

    Article • BMJ Paediatrics Open, October 2022, BMJ

    Dr. Bolajoko O. Olusanya, Wei Zhao

  44. Clinical utility of a model‐based amoxicillin dosage regimen in neonates with early‐onset sepsis

    Article • British Journal of Clinical Pharmacology, September 2022, Wiley

    Wei Zhao

  45. Optimal dose of cefotaxime in neonates with early-onset sepsis: A developmental pharmacokinetic model-based evaluation

    Article • Frontiers in Pharmacology, September 2022, Frontiers

    Wei Zhao

  46. Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients

    Article • Frontiers in Pharmacology, August 2022, Frontiers

    Wei Zhao

  47. Guideline for the management of pediatric off-label use of drugs in China (2021)

    Article • BMC Pediatrics, July 2022, Springer Science + Business Media

    Wei Zhao

  48. Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants

    Article • Journal of Antimicrobial Chemotherapy, June 2022, Oxford University Press (OUP)

    Wei Zhao

  49. Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation

    Article • Clinical Pharmacokinetics, May 2022, Springer Science + Business Media

    Wei Zhao

  50. Optimal dose of meropenem for the treatment of neonatal sepsis: Dosing guideline variations and clinical practice deviations

    Article • British Journal of Clinical Pharmacology, March 2022, Wiley

    Wei Zhao

  51. Optimal Sample Size for Use in Neonatal Pharmacokinetic Studies

    Article • Therapeutic Innovation & Regulatory Science, January 2022, Springer Science + Business Media

    Wei Zhao

  52. Clinical utiliy of a model‐based piperacillin dose in neonates with early‐onset sepsis

    Article • British Journal of Clinical Pharmacology, September 2021, Wiley

    Wei Zhao

  53. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance

    Article • Antimicrobial Agents and Chemotherapy, September 2021, ASM Journals

    Wei Zhao

  54. A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography/tandem mass spectrometry

    Article • Journal of Chromatography B, September 2021, Elsevier

    Wei Zhao

  55. Editorial: Model-Based Evaluation of Antimicrobial Agents in Children

    Article • Frontiers in Pharmacology, August 2021, Frontiers

    Wei Zhao

  56. LPS-Induced Inflammation Affects Midazolam Clearance in Juvenile Mice in an Age-Dependent Manner

    Article • Journal of Inflammation Research, August 2021, Taylor & Francis

    Wei Zhao

  57. Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis

    Article • European Journal of Pharmaceutical Sciences, August 2021, Elsevier

    Wei Zhao

  58. A Validated LC-MS/MS Method for the Determination of Mezlocillin in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children

    Article • Current Pharmaceutical Analysis, August 2021, Elsevier

    Wei Zhao

  59. Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

    Article • British Journal of Clinical Pharmacology, July 2021, Wiley

    Professor karel allegaert , Wei Zhao

  60. Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia

    Article • Clinical Pharmacokinetics, July 2021, Springer Science + Business Media

    Wei Zhao

  61. Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug

    Article • Frontiers in Pharmacology, July 2021, Frontiers

    Wei Zhao

  62. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients

    Article • Frontiers in Pharmacology, July 2021, Frontiers

    Wei Zhao

  63. Latamoxef for Neonates With Early-Onset Neonatal Sepsis: A Study Protocol for a Randomized Controlled Trial

    Article • Frontiers in Pharmacology, June 2021, Frontiers

    Wei Zhao

  64. Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction

    Article • Clinical Pharmacokinetics, May 2021, Springer Science + Business Media

    Professor karel allegaert , Wei Zhao

  65. Downregulation of Renal MRPs Transporters in Acute Lymphoblastic Leukemia Mediated by the IL-6/STAT3/PXR Signaling Pathway

    Article • Journal of Inflammation Research, May 2021, Taylor & Francis

    Wei Zhao

  66. Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia

    Article • Drug Design Development and Therapy, April 2021, Taylor & Francis

    Wei Zhao

  67. Serum Creatinine and Serum Cystatin C are Both Relevant Renal Markers to Estimate Vancomycin Clearance in Critically Ill Neonates

    Article • Frontiers in Pharmacology, March 2021, Frontiers

    Wei Zhao

  68. Population Pharmacokinetic Study of Cefathiamidine in Infants With Augmented Renal Clearance

    Article • Frontiers in Pharmacology, March 2021, Frontiers

    Wei Zhao

  69. Off‐label use of letrozole in Chinese short pubertal boys: Effectiveness, safety, and exposure–response analysis

    Article • British Journal of Clinical Pharmacology, March 2021, Wiley

    Wei Zhao

  70. Pharmacokinetics and safety of pegylated recombinant human granulocyte colony‐stimulating factor in children with acute leukaemia

    Article • British Journal of Clinical Pharmacology, February 2021, Wiley

    Wei Zhao

  71. Effects of continuous venovenous hemofiltration on vancomycin trough concentrations in critically ill children

    Article • Annals of Translational Medicine, February 2021, AME Publishing Company

    Wei Zhao

  72. Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation

    Article • Antimicrobial Agents and Chemotherapy, December 2020, ASM Journals

    Wei Zhao

  73. Oral drugs used to treat persistent pulmonary hypertension of the newborn

    Article • Expert Review of Clinical Pharmacology, December 2020, Taylor & Francis

    Wei Zhao

  74. Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society

    Article • Clinical Infectious Diseases, November 2020, Oxford University Press (OUP)

    Zheng Jiao, Wei Zhao

  75. Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study

    Article • Journal of Antimicrobial Chemotherapy, November 2020, Oxford University Press (OUP)

    Professor karel allegaert , Wei Zhao

  76. Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus

    Article • Medicine, November 2020, Wolters Kluwer Health

    Wei Zhao

  77. Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis

    Article • Antimicrobial Agents and Chemotherapy, October 2020, ASM Journals

    Wei Zhao

  78. Cefotiam Treatment in Children: Evidence of Subtherapeutic Levels

    Article • Therapeutic Drug Monitoring, October 2020, Wolters Kluwer Health

    Wei Zhao

  79. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Chinese Infants

    Article • The Journal of Clinical Pharmacology, September 2020, Wiley

    Wei Zhao

  80. Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate

    Article • Frontiers in Pharmacology, September 2020, Frontiers

    Wei Zhao

  81. Extremely low dose of 6‐mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations

    Article • Journal of Clinical Pharmacy and Therapeutics, September 2020, Wiley

    Wei Zhao

  82. Determination of Loratadine and Its Active Metabolite in Plasma by LC/MS/MS: An Adapted Method for Children

    Article • Current Pharmaceutical Analysis, August 2020, Bentham Science Publishers

    Wei Zhao

  83. Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration

    Article • Pharmaceutical Research, August 2020, Springer Science + Business Media

    Wei Zhao

  84. Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post‐marketing study to support paediatric labelling in China

    Article • British Journal of Clinical Pharmacology, July 2020, Wiley

    Wei Zhao

  85. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis

    Article • Antimicrobial Agents and Chemotherapy, July 2020, ASM Journals

    Wei Zhao

  86. Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia

    Article • European Journal of Clinical Pharmacology, June 2020, Springer Science + Business Media

    Wei Zhao

  87. First dose in neonates: pharmacokinetic bridging study from juvenile mice to neonates for drugs metabolized by CYP3A

    Article • Xenobiotica, May 2020, Taylor & Francis

    Wei Zhao

  88. An adapted LC-MS/MS method for the determination of free plasma concentration of cefoperazone in children: Age-dependent protein binding

    Article • Journal of Chromatography B, May 2020, Elsevier

    Wei Zhao

  89. PK/PD modeling of 5‐hydroxytryptophan (5‐HTP) challenge test with cortisol measurement in serum and saliva

    Article • Pharmacology Research & Perspectives, March 2020, Wiley

    Wei Zhao

  90. Developmental population pharmacokinetics–pharmacodynamics and dosing optimization of cefoperazone in children

    Article • Journal of Antimicrobial Chemotherapy, March 2020, Oxford University Press (OUP)

    Wei Zhao

  91. Paediatric drugs trials in China

    Article • BMJ Paediatrics Open, March 2020, BMJ

    Wei Zhao

  92. Precision therapy of 6‐mercaptopurine in Chinese children with acute lymphoblastic leukemia

    Article • British Journal of Clinical Pharmacology, February 2020, Wiley

    Wei Zhao

  93. Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants

    Article • Frontiers in Pharmacology, February 2020, Frontiers

    Wei Zhao

  94. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China

    Article • Antimicrobial Agents and Chemotherapy, January 2020, ASM Journals

    Wei Zhao

  95. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology

    Article • European Journal of Pediatrics, January 2020, Springer Science + Business Media

    Wei Zhao, Professor karel allegaert

  96. Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children

    Article • Drug Design Development and Therapy, December 2019, Taylor & Francis

    Wei Zhao

  97. Off‐label use of tacrolimus in children with glomerular disease: Effectiveness, Safety and Pharmacokinetics

    Article • British Journal of Clinical Pharmacology, November 2019, Wiley

    Wei Zhao

  98. Population Pharmacokinetics of Ganciclovir after Valganciclovir Treatment in Children with Renal Transplant

    Article • Antimicrobial Agents and Chemotherapy, September 2019, ASM Journals

    Wei Zhao

  99. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants

    Article • Journal of Antimicrobial Chemotherapy, May 2019, Oxford University Press (OUP)

    Wei Zhao, Professor karel allegaert

  100. Optimisation of vancomycin exposure in neonates based on the best level of evidence

    Article • Pharmacological Research, May 2019, Elsevier

    Wei Zhao

  101. Body Surface Area-Based Dosing Regimen of Caspofungin in Children: a Population Pharmacokinetics Confirmatory Study

    Article • Antimicrobial Agents and Chemotherapy, April 2019, ASM Journals

    Wei Zhao

  102. Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies

    Article • Antimicrobial Agents and Chemotherapy, April 2019, ASM Journals

    Wei Zhao

  103. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants

    Article • Antimicrobial Agents and Chemotherapy, December 2018, ASM Journals

    Wei Zhao

  104. Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants

    Article • International Journal of Antimicrobial Agents, November 2018, Elsevier

    Wei Zhao

  105. Early target attainment of azithromycin therapy in children with lower respiratory tract infections

    Article • Journal of Antimicrobial Chemotherapy, July 2018, Oxford University Press (OUP)

    Wei Zhao

  106. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia

    Article • Antimicrobial Agents and Chemotherapy, June 2018, ASM Journals

    Wei Zhao

  107. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial

    Article • British Journal of Clinical Pharmacology, June 2018, Wiley

    Wei Zhao

  108. A Sensitive Microscale HPLC-UV Method for the Determination of Doxofylline and its Metabolites in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children

    Article • Current Pharmaceutical Analysis, June 2018, Bentham Science Publishers

    Wei Zhao

  109. Aciclovir CSF concentration in children with viral encephalitis: is it adequate?

    Article • Journal of Antimicrobial Chemotherapy, June 2018, Oxford University Press (OUP)

    Wei Zhao

  110. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome

    Article • British Journal of Clinical Pharmacology, May 2018, Wiley

    Wei Zhao

  111. A microscale HPLC-UV method for the determination of latamoxef in plasma: An adapted method for therapeutic drug monitoring in neonates

    Article • Biomedical Chromatography, April 2018, Wiley

    Wei Zhao

  112. Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection

    Article • Drug Design Development and Therapy, April 2018, Dove Medical Press

    Wei Zhao

  113. Principles and applications of pharmacometrics in drug evaluation in children

    Article • Therapies, April 2018, Elsevier

    Wei Zhao

  114. Off-label use of tacrolimus in children with Henoch-Schönlein purpura nephritis: a pilot study

    Article • Archives of Disease in Childhood, March 2018, BMJ

    Wei Zhao

  115. Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug

    Article • British Journal of Clinical Pharmacology, March 2018, Wiley

    Wei Zhao

  116. Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection

    Article • Antimicrobial Agents and Chemotherapy, March 2018, ASM Journals

    Wei Zhao

  117. Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants

    Article • Antimicrobial Agents and Chemotherapy, February 2018, ASM Journals

    Wei Zhao

  118. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus

    Article • Pediatric Nephrology, February 2018, Springer Science + Business Media

    Wei Zhao

  119. Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease

    Article • Antimicrobial Agents and Chemotherapy, January 2018, ASM Journals

    Wei Zhao

  120. Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants

    Article • Antimicrobial Agents and Chemotherapy, January 2018, ASM Journals

    Wei Zhao

  121. Determination of cefoperazone and sulbactam in serum by HPLC-MS/MS: An adapted method for therapeutic drug monitoring in children

    Article • Biomedical Chromatography, December 2017, Wiley

    Wei Zhao

  122. Commentary on the MID3 Good Practices Paper

    Article • CPT Pharmacometrics & Systems Pharmacology, July 2017, Wiley

    Wei Zhao

  123. Posologie des antibiotiques chez le nouveau-né : variations des pratiques et comment y remédier ?

    Article • Archives de Pédiatrie, September 2016, Elsevier

    Wei Zhao

  124. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants

    Article • Antimicrobial Agents and Chemotherapy, August 2016, ASM Journals

    Wei Zhao

  125. Safety study of Ciprofloxacin in newborn mice

    Article • Regulatory Toxicology and Pharmacology, February 2016, Elsevier

    Wei Zhao

  126. Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates

    Article • Antimicrobial Agents and Chemotherapy, January 2016, ASM Journals

    Wei Zhao

  127. Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates

    Article • Journal of Antimicrobial Chemotherapy, January 2016, Oxford University Press (OUP)

    Wei Zhao

  128. Author’s Reply to Standing et al. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design

    Article • Clinical Pharmacokinetics, November 2015, Springer Science + Business Media

    Wei Zhao

  129. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease

    Article • British Journal of Clinical Pharmacology, September 2015, Wiley

    Wei Zhao

  130. How to use vancomycin optimally in neonates: remaining questions

    Article • Expert Review of Clinical Pharmacology, August 2015, Taylor & Francis

    Wei Zhao

  131. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design

    Article • Clinical Pharmacokinetics, June 2015, Springer Science + Business Media

    Wei Zhao

  132. Cystatin C as a potential biomarker for dosing of renally excreted drugs

    Article • British Journal of Clinical Pharmacology, May 2015, Wiley

    Wei Zhao

  133. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey

    Article • Archives of Disease in Childhood, January 2015, BMJ

    Wei Zhao

  134. Impact of Glutathione S-Transferase M1 and T1 on Anti-Tuberculosis Drug–Induced Hepatotoxicity in Chinese Pediatric Patients

    Article • PLOS One, December 2014, PLOS

    Wei Zhao

  135. Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder

    Article • Drug Design Development and Therapy, December 2014, Taylor & Francis

    Wei Zhao

  136. Choosing the right dose of tacrolimus

    Article • Archives of Disease in Childhood, November 2014, BMJ

    Wei Zhao

  137. First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro–In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole

    Article • Clinical Pharmacokinetics, August 2014, Springer Science + Business Media

    Wei Zhao

  138. Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age

    Article • Antimicrobial Agents and Chemotherapy, August 2014, ASM Journals

    Wei Zhao

  139. Dosage individualization in children: integration of pharmacometrics in clinical practice

    Article • World Journal of Pediatrics, August 2014, Springer Science + Business Media

    Wei Zhao

  140. A model‐based approach for the evaluation of once daily dosing of lamivudine in HIV‐infected children

    Article • British Journal of Clinical Pharmacology, April 2014, Wiley

    Oscar Della Pasqua, Wei Zhao

  141. Covariate effects and population pharmacokinetics of lamivudine in HIV‐infected children

    Article • British Journal of Clinical Pharmacology, April 2014, Wiley

    Oscar Della Pasqua, Wei Zhao

  142. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease

    Article • Antimicrobial Agents and Chemotherapy, March 2014, ASM Journals

    Wei Zhao

  143. Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection

    Article • Journal of Antimicrobial Chemotherapy, November 2013, Oxford University Press (OUP)

    Wei Zhao

  144. Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates

    Article • Clinical Pharmacokinetics, September 2013, Springer Science + Business Media

    Wei Zhao

  145. The Importance of Knowing How Vancomycin is Measured When Interpreting Its Pharmacokinetic Results

    Article • Therapeutic Drug Monitoring, June 2013, Wolters Kluwer Health

    Wei Zhao

  146. Population pharmacokinetics of abacavir in infants, toddlers and children

    Article • British Journal of Clinical Pharmacology, May 2013, Wiley

    Oscar Della Pasqua, Wei Zhao

  147. Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration

    Article • Acta Pharmacologica Sinica, April 2013, Nature

    Wei Zhao

  148. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings

    Article • British Journal of Clinical Pharmacology, March 2013, Wiley

    Professor karel allegaert , Wei Zhao

  149. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration

    Article • Seminars in Fetal and Neonatal Medicine, February 2013, Elsevier

    Wei Zhao

  150. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring

    Article • Archives of Disease in Childhood, December 2012, BMJ

    Wei Zhao

  151. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children

    Article • European Journal of Clinical Pharmacology, December 2012, Springer Science + Business Media

    Wei Zhao

  152. Pharmacogenetic Determinant of the Drug Interaction Between Tacrolimus and Omeprazole

    Article • Therapeutic Drug Monitoring, December 2012, Wolters Kluwer Health

    Wei Zhao

  153. Optimizing Micafungin Dosing in Children

    Article • The Pediatric Infectious Disease Journal, November 2012, Wolters Kluwer Health

    Wei Zhao

  154. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients

    Article • European Journal of Clinical Pharmacology, June 2012, Springer Science + Business Media

    Wei Zhao

  155. Individualization of Valganciclovir Prophylaxis for Cytomegalovirus Infection in Pediatric Kidney Transplant Patients

    Article • Therapeutic Drug Monitoring, June 2012, Wolters Kluwer Health

    Wei Zhao

  156. Pharmacokinetic Interaction Between Tacrolimus and Amlodipine in a Renal Transplant Child

    Article • Transplantation, April 2012, Wolters Kluwer Health

    Wei Zhao

  157. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV‐infected infants and toddlers

    Article • British Journal of Clinical Pharmacology, March 2012, Wiley

    Oscar Della Pasqua, Wei Zhao

  158. Limited Sampling Strategy for Estimating Individual Exposure of Tacrolimus in Pediatric Kidney Transplant Patients

    Article • Therapeutic Drug Monitoring, December 2011, Wolters Kluwer Health

    Wei Zhao

  159. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?

    Article • British Journal of Clinical Pharmacology, August 2011, Wiley

    Oscar Della Pasqua, Wei Zhao

  160. Principles of Therapeutic Drug Monitoring

    Article • January 2011, Springer Science + Business Media

    Wei Zhao

  161. Developmental Pharmacogenetics of Immunosuppressants in Pediatric Organ Transplantation

    Article • Therapeutic Drug Monitoring, December 2010, Wolters Kluwer Health

    Wei Zhao

  162. Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal-Transplant Patients

    Article • The Journal of Clinical Pharmacology, November 2010, Wiley

    Wei Zhao

  163. Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: An adapted method for neonates

    Article • Biomedical Chromatography, September 2010, Wiley

    Wei Zhao

  164. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome

    Article • British Journal of Clinical Pharmacology, April 2010, Wiley

    Wei Zhao

  165. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months

    Article • Antiviral Therapy, January 2010, International Medical Press

    Wei Zhao

  166. Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients

    Article • Clinical Pharmacology & Therapeutics, October 2009, Nature

    Wei Zhao

  167. Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients

    Article • Clinical Pharmacokinetics, May 2009, Springer Science + Business Media

    Wei Zhao